Physician profile
John Madigan
NPI 1427239854
$2,411.16
in general payments reported to CMS, 2019-2025
21 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $101 · 2021: $341 · 2022: $38.85 · 2023: $151 · 2024: $785 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Education: $26.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.93 |
| Education | $26.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $392.92 | 2019-2025 | Farxiga, Lokelma |
| Esperion Therapeutics, INC. | $304.11 | 2020-2021 | |
| Amgen INC. | $263.07 | 2024-2025 | Tavneos |
| Abbvie INC. | $227.20 | 2024-2025 | |
| Ardelyx, INC. | $206.17 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $152.26 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $130.26 | 2019 | |
| Aurinia Pharma U.S., INC. | $113.11 | 2025 | Lupkynis |
| Pharmacosmos Therapeutics INC. | $108.53 | 2024 | Monoferric |
| La Jolla Pharmaceutical Company | $97.05 | 2025 | Giapreza |
| Nxstage Medical, INC. | $91.05 | 2025 | Nxstage System One |
| Akebia Therapeutics INC | $69.31 | 2024-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $47.53 | 2023-2024 | Tarpeyo |
| Vifor Pharma, INC. | $43.83 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $36.87 | 2025 | Voyxact, Jynarque |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $29.21 | 2022-2023 | Krystexxa |
| Genzyme Corporation | $25.32 | 2023 | |
| Fresenius USA Marketing, INC. | $24.62 | 2023 | Velphoro |
| Travere Therapeutics, INC. | $19.70 | 2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $16.25 | 2025 | |
| Novo Nordisk INC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Madigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.